Paul Hanna, MD, MSc

Publications

• Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer.

  (Hanna PE, Ouyang T, Tahir I, Katz-Agranov N, Wang Q, Mantz L, Strohbehn I, Moreno D, Harden D, Dinulos JE, Cosar D, Seethapathy H, Gainor JF, Shah SJ, Gupta S, Leaf DE, Fintelmann FJ, Sise ME.) J Cachexia Sarcopenia Muscle. 2024 Apr 22 PMID: 38646842 SCOPUS ID: 2-s2.0-85191144047 04/22/2024

• Challenges for optimal care in onconephrology.

  (Hanna PE, Chowdhury R, Solhjou Z, Gupta S, Jhaveri KD.) Nephrol Dial Transplant. 2024 Jan 31;39(2):167-169 PMID: 37442629 PMCID: PMC10828197 SCOPUS ID: 2-s2.0-85183980722 07/14/2023

• Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.

  (Hanna PE, Strohbehn IA, Moreno D, Harden D, Seethapathy R, Sawtell R, Wang Q, Ouyang T, Katz-Agranov N, Dinulos J, Wander SA, Gupta S, Sise ME.) NPJ Breast Cancer. 2023 Aug 19;9(1):70 PMID: 37598278 PMCID: PMC10439887 08/20/2023

• Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure.

  (Cho WJ, Harden D, Moreno D, Dinulos JE, Hanna PE, Wang Q, Kim AY, Sise ME.) Nephrol Dial Transplant. 2023 Jul 31;38(8):1912-1914 PMID: 36948600 PMCID: PMC10387392 SCOPUS ID: 2-s2.0-85166383260 03/23/2023

• Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.

  (Gupta S, Hanna PE, Ouyang T, Yamada KS, Sawtell R, Wang Q, Katz-Agranov N, Feghali L, Krasner CN, Bouberhan S, Castro CM, Sise ME.) J Natl Cancer Inst. 2023 Jul 06;115(7):831-837 PMID: 37074956 PMCID: PMC10323894 SCOPUS ID: 2-s2.0-85159271658 04/19/2023

• Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.

  (Hanna PE, Wang Q, Strohbehn IA, Moreno D, Harden D, Ouyang T, Katz-Agranov N, Seethapathy H, Reynolds KL, Gupta S, Leaf DE, Sise ME.) JAMA Netw Open. 2023 Jul 03;6(7):e2321715 PMID: 37405775 PMCID: PMC10323710 SCOPUS ID: 2-s2.0-85163940967 07/05/2023

• Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

  (Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, Gooptu M, Kelkar AH, Wells SL, Nikiforow S, Koreth J, Romee R, Soiffer RJ, Shapiro RM, Gupta S.) Transplant Cell Ther. 2023 Jul;29(7):455.e1-455.e9 PMID: 37015320 PMCID: PMC10330095 SCOPUS ID: 2-s2.0-85158889828 04/05/2023

• Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.

  (Tiu BC, Strohbehn IA, Zhao S, Ouyang T, Hanna P, Wang Q, Gupta S, Leaf DE, Reynolds KL, Sise ME.) Oncologist. 2023 Jun 02;28(6):e379-e390 PMID: 36821637 PMCID: PMC10243781 SCOPUS ID: 2-s2.0-85162195179 02/24/2023

• Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR.

  (Hanna PE, Wang Q, Strohbehn I, Moreno D, Harden D, Ouyang T, Katz-Agranov N, Seethapathy H, Reynolds KL, Gupta S, Leaf DE, Sise ME.) medRxiv. 2023 Jan 18 PMID: 36711583 PMCID: PMC9882433 01/31/2023

• Pyelonephritis is an Underrecognized Cause of CKD in Patients With Orthotopic Ileal Neobladder Substitution

  (Wang Q, Seethapathy R, Ouyang T, Strohbehn IA, Katz-Agranov N, Hanna P, Madken M, Seethapathy H, Gupta S, Heller HM, Wszolek M, Steele D, Klepeis VE, Rennke H, Sise ME.) Kidney International Reports. December 2023;8(12):2833-2837 SCOPUS ID: 2-s2.0-85173386703 12/01/2023

• Risk Factors for Severe Hypertension and Proteinuria after Treatment with Vascular Endothelial Growth Factor Signaling Pathway Inhibitors among Patients with Cancer

  (Hanna PE, Anumolu RK, Motwani SS, Chen KL, Katz-Agranov N, Green-Lingren O, Yilmam OA, Jhaveri KD, Kitchlu A, Kala J, Sise ME, Gupta S.) Kidney International Reports. doi: 10.1016/j.ekir.2024.03.005 03/13/2024

• Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma

  (Mistry K, Zhao S, Strohbehn I, Wang Q, Hanna P, Strohbehn S, Katz-Agranov N, Sullivan RJ, Sise M.) Nephrology Dialysis Transplantation. doi:10.1093/ndt/gfae049 02/22/2024